Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems
Volition (NYSE AMERICAN: VNRX) completed validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q® Vet Cancer Test with Fujifilm Vet Systems in Japan, enabling full automation in central laboratories.
Rhea-AI Summary
Volition (NYSE AMERICAN: VNRX) completed validation and verification of the chemiluminescent immunoassay (ChLIA) version of its Nu.Q® Vet Cancer Test with Fujifilm Vet Systems in Japan, enabling full automation in central laboratories.
The supply agreement allows Fujifilm Vet Systems to sell and perform the automated test across its Japanese central reference lab network; over 1,700 veterinary hospitals are registered and Japan has about 7 million pet dogs, indicating a sizeable addressable market.
Positive
- Validation completed for automated ChLIA Nu.Q Vet test in Japan
- Supply agreement lets Fujifilm sell and perform test in Japan
- More than 1,700 veterinary hospitals in Japan registered to use test
Negative
- No revenue, pricing, or launch volumes disclosed in the announcement
Details
News Market Reaction – VNRX
On Mar 6, the day this news came out, VNRX closed 0.66% above the previous close.
Data tracked by StockTitan Argus for the Mar 6 session.
Key Figures
- Pet dogs in Japan
- 7,000,000 dogs
- Stated companion animal population relevant to Nu.Q® Vet Cancer Test market
- Registered vet hospitals
- 1,700+ hospitals
- Japanese veterinary hospitals registered to use Nu.Q® Vet Cancer Test since July 2024 launch
Historical Context
-
Highlighted multi‑pillar commercial progress and clinical milestones across Nu.Q® portfolio.
-
Named new Japanese distributor for Nu.Q® Discover and cited ~$1B TAM.
-
Received NYSE American notice for stockholders’ equity listing standard non‑compliance.
-
Presented Nu.Q® NETs HS data and highlighted CE‑marked status and $3.8B TAM.
-
Preparing French reimbursement dossier for Nu.Q® Cancer assays with HCL support.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
chemiluminescent immunoassay (chlia) medical
automated analyzer technical
central laboratories technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Junichi Makino, President and Representative Director at Fujifilm Vet Systems, said:
"We are excited to be the first in the world to utilize this centralized lab automation for the Nu.Q® Vet Cancer Test, this is a big step forward from the current use of manual plates.
"Since our launch of the Nu.Q® Vet Cancer Test in July 2024, there has been an incredible amount of interest amongst Japanese veterinarians, indeed the number of veterinary hospitals registered to use the test in
"This automated test will enable a more rapid turnaround and high throughput to meet increasing demand."
Dr. Jasmine Kway, Chief Executive Officer of Singapore Volition added:
"There are approximately seven million pet dogs in
"Cancer is the leading cause of adult canine deaths and earlier detection can improve outcomes. The Nu.Q® Vet Cancer Test is an accessible and affordable screening tool for dogs to aid in early cancer detection.
"This automated test via the Immunodiagnostic Systems (IDS) i10® automated analyzer platform is the same platform Volition utilizes for its human products: Nu.Q® Cancer, Nu.Q® NETs and Nu.Q® Discover, demonstrating the synergy across not only the Nu.Q® technology platform but also between humans and dogs."
Volition's supply agreement enables Fujifilm Vet Systems to sell and perform the Nu.Q® Vet Cancer Test throughout its network of central reference laboratories in Japan.
About FujiFilm Vet Systems
FujiFilm Vet Systems is a subsidiary of FujiFilm Holdings Corporation, listed on the
FujiFilm Vet Systems provides testing services centered on health checkups to veterinary medical facilities nationwide with relationships throughout the estimated 11,000 veterinary medical facilities in
About Volition
Volition is a multi-national epigenetics company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of
View original content:https://www.prnewswire.com/news-releases/volition-announces-first-ever-automated-nuq-vet-cancer-test-with-fujifilm-vet-systems-302706601.html
SOURCE VolitionRx Limited
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.